OncoSil Medical Surges with Record Sales and $8.7M Capital Boost
OncoSil Medical has reported a record 20% quarterly increase in dose sales and secured $8.7 million in new capital, underpinning its clinical and commercial expansion in pancreatic cancer treatment.
- Record 20% quarterly dose sales growth in Q4 FY25
- 42% full-year dose sales increase driving 66% revenue uplift
- Completed $8.7 million capital raise including oversubscribed $2 million Share Purchase Plan
- Initiation of European clinical study tender by Germany’s G-BA
- Superior clinical outcomes demonstrated versus SBRT in real-world study
Strong Commercial Momentum
OncoSil Medical Ltd (ASX, OSL) has delivered an impressive close to FY25, reporting a 20% increase in quarterly dose sales of its OncoSil™ device, a targeted brachytherapy treatment for unresectable locally advanced pancreatic cancer (LAPC). This growth marks a new quarterly record and contributes to a 42% rise in dose sales for the full year, which in turn fueled a 66% uplift in annual revenue. The company attributes this momentum to expanded hospital networks, increased procedural frequency, and heightened clinical awareness.
Capital Raise Fuels Growth and Trials
To support its commercialisation and clinical development efforts, OncoSil Medical successfully completed an $8.7 million capital raise during the quarter, comprising a two-tranche placement and a strongly oversubscribed $2 million Share Purchase Plan (SPP). These funds are earmarked for advancing clinical trials, operational costs, and working capital, positioning the company to reach positive operating cash flow by the second half of calendar 2026.
Clinical Advances and Regulatory Progress
On the clinical front, OncoSil™ demonstrated superior outcomes compared to Stereotactic Body Radiation Therapy (SBRT) in a retrospective study presented at Digestive Disease Week 2025. Patients treated with OncoSil™ showed significantly improved overall survival (median 22 months vs 14 months), progression-free survival, tumor downstaging, and surgical resection rates. Meanwhile, Germany’s Federal Joint Committee (G-BA) initiated a European-wide tender to appoint a Contract Research Organisation to conduct a pivotal clinical study on OncoSil™, a critical step toward securing national reimbursement.
Expanding Global Footprint and Clinical Trials
OncoSil Medical also expanded its international reach by signing an exclusive distribution agreement with Pro-Gem for Slovenia. Additionally, patient recruitment completed for two key clinical trials, the PANCOSIL study, exploring a novel CT-guided delivery method, and the TRIPP-FFX trial assessing OncoSil™ alongside FOLFIRINOX chemotherapy. Data from these studies are expected in late 2025 and early 2026, respectively, potentially unlocking new treatment pathways and market opportunities.
Financial Position and Outlook
At quarter-end, OncoSil held $5.121 million in cash and equivalents, with operating cash outflows of $3.296 million primarily driven by staff costs and research and development. The company’s recent capital raise and ongoing cost management efforts provide a runway through mid-2026, supporting its strategic growth initiatives. CEO Nigel Lange expressed confidence in building on the current momentum to broaden patient access and advance clinical evidence.
Bottom Line?
OncoSil Medical’s record sales and robust capital position set the stage for critical clinical data releases and potential reimbursement milestones in the year ahead.
Questions in the middle?
- Will upcoming PANCOSIL and TRIPP-FFX trial data confirm OncoSil’s clinical advantages?
- How will the outcome of the G-BA tender influence OncoSil’s reimbursement and market access in Europe?
- Can OncoSil sustain its sales growth trajectory amid competitive and regulatory challenges?
